186 related articles for article (PubMed ID: 34251713)
1. Role of BCLAF-1 in PD-L1 stabilization in response to ionizing irradiation.
Ma Z; Wang H; Meng F; Han Y; Chen Y; Xiao M; Jiang H; Yu Z; Xu B
Cancer Sci; 2021 Oct; 112(10):4064-4074. PubMed ID: 34251713
[TBL] [Abstract][Full Text] [Related]
2. CMTM6, a potential immunotherapy target.
Liang J; Li S; Li W; Rao W; Xu S; Meng H; Zhu F; Zhai D; Cui M; Xu D; Cai J; Zhang B
J Cancer Res Clin Oncol; 2022 Jan; 148(1):47-56. PubMed ID: 34783871
[TBL] [Abstract][Full Text] [Related]
3. High linear energy transfer carbon-ion irradiation upregulates PD-L1 expression more significantly than X-rays in human osteosarcoma U2OS cells.
Permata TBM; Sato H; Gu W; Kakoti S; Uchihara Y; Yoshimatsu Y; Sato I; Kato R; Yamauchi M; Suzuki K; Oike T; Tsushima Y; Gondhowiardjo S; Ohno T; Yasuhara T; Shibata A
J Radiat Res; 2021 Sep; 62(5):773-781. PubMed ID: 34196706
[TBL] [Abstract][Full Text] [Related]
4. BCLAF1 binds SPOP to stabilize PD-L1 and promotes the development and immune escape of hepatocellular carcinoma.
Yu Z; Wu X; Zhu J; Yan H; Li Y; Zhang H; Zhong Y; Lin M; Ye G; Li X; Jin J; Li K; Wang J; Zhuang H; Lin T; He J; Lu C; Xu Z; Zhang X; Li H; Jin X
Cell Mol Life Sci; 2024 Feb; 81(1):82. PubMed ID: 38340178
[TBL] [Abstract][Full Text] [Related]
5. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators.
Mezzadra R; Sun C; Jae LT; Gomez-Eerland R; de Vries E; Wu W; Logtenberg MEW; Slagter M; Rozeman EA; Hofland I; Broeks A; Horlings HM; Wessels LFA; Blank CU; Xiao Y; Heck AJR; Borst J; Brummelkamp TR; Schumacher TNM
Nature; 2017 Sep; 549(7670):106-110. PubMed ID: 28813410
[TBL] [Abstract][Full Text] [Related]
6. CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1.
Miao B; Hu Z; Mezzadra R; Hoeijmakers L; Fauster A; Du S; Yang Z; Sator-Schmitt M; Engel H; Li X; Broderick C; Jin G; Gomez-Eerland R; Rozeman L; Lei X; Matsuo H; Yang C; Hofland I; Peters D; Broeks A; Laport E; Fitz A; Zhao X; Mahmoud MAA; Ma X; Sander S; Liu HK; Cui G; Gan Y; Wu W; Xiao Y; Heck AJR; Guan W; Lowe SW; Horlings HM; Wang C; Brummelkamp TR; Blank CU; Schumacher TNM; Sun C
Cancer Cell; 2023 Oct; 41(10):1817-1828.e9. PubMed ID: 37683639
[TBL] [Abstract][Full Text] [Related]
7. Ataxia telangiectasia mutated kinase inhibition promotes irradiation-induced PD-L1 expression in tumour-associated macrophages through IFN-I/JAK signalling pathway.
Gao Y; Li Y; Lin Z; Zeng Y; Huang Z; Han L; Zhong Y; Gong Y; Wu Q; Xie C
Immunology; 2023 Feb; 168(2):346-361. PubMed ID: 36326481
[TBL] [Abstract][Full Text] [Related]
8. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.
Deng L; Liang H; Burnette B; Beckett M; Darga T; Weichselbaum RR; Fu YX
J Clin Invest; 2014 Feb; 124(2):687-95. PubMed ID: 24382348
[TBL] [Abstract][Full Text] [Related]
9. CMTM6 and CMTM7: New leads for PD-L1 regulation in breast cancer cells undergoing EMT.
Xiao M; Duhem C; Chammout A; Berchem G; Janji B
J Cell Biochem; 2022 Jun; 123(6):1025-1031. PubMed ID: 35575054
[TBL] [Abstract][Full Text] [Related]
10. CMTM6-Deficient Monocytes in ANCA-Associated Vasculitis Fail to Present the Immune Checkpoint PD-L1.
Zeisbrich M; Chevalier N; Sehnert B; Rizzi M; Venhoff N; Thiel J; Voll RE
Front Immunol; 2021; 12():673912. PubMed ID: 34108971
[TBL] [Abstract][Full Text] [Related]
11. CMTM6 as a master regulator of PD-L1.
Yaseen MM; Abuharfeil NM; Darmani H
Cancer Immunol Immunother; 2022 Oct; 71(10):2325-2340. PubMed ID: 35294592
[TBL] [Abstract][Full Text] [Related]
12. Analysis of programmed death-ligand 1 expression in primary normal human dermal fibroblasts after DNA damage.
Hagiwara Y; Sato H; Permata TBM; Niimi A; Yamauchi M; Oike T; Nakano T; Shibata A
Hum Immunol; 2018 Aug; 79(8):627-631. PubMed ID: 29859207
[TBL] [Abstract][Full Text] [Related]
13. Molecular and immune characteristics for lung adenocarcinoma patients with CMTM6 overexpression.
Wang H; Gao J; Zhang R; Li M; Peng Z; Wang H
Int Immunopharmacol; 2020 Jun; 83():106478. PubMed ID: 32278132
[TBL] [Abstract][Full Text] [Related]
14. BCLAF1-induced HIF-1α accumulation under normoxia enhances PD-L1 treatment resistances via BCLAF1-CUL3 complex.
Yao B; Lu Y; Li Y; Bai Y; Wei X; Yang Y; Yao D
Cancer Immunol Immunother; 2023 Dec; 72(12):4279-4292. PubMed ID: 37906282
[TBL] [Abstract][Full Text] [Related]
15. CMTM6 Stabilizes PD-L1 Expression and Is a New Prognostic Impact Factor in Hepatocellular Carcinoma.
Yugawa K; Itoh S; Yoshizumi T; Iseda N; Tomiyama T; Morinaga A; Toshima T; Harada N; Kohashi K; Oda Y; Mori M
Hepatol Commun; 2021 Feb; 5(2):334-348. PubMed ID: 33553979
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 is induced on the hepatocyte surface via CKLF-like MARVEL transmembrane domain-containing protein 6 up-regulation by the anti-HBV drug Entecavir.
Yamamoto Y; Kakizaki M; Shimizu T; Carreras J; Chiba T; Chamoto K; Kagawa T; Aoki T; Nakamura N; Ando K; Kotani A
Int Immunol; 2020 Jul; 32(8):519-531. PubMed ID: 32219331
[TBL] [Abstract][Full Text] [Related]
17. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity.
Burr ML; Sparbier CE; Chan YC; Williamson JC; Woods K; Beavis PA; Lam EYN; Henderson MA; Bell CC; Stolzenburg S; Gilan O; Bloor S; Noori T; Morgens DW; Bassik MC; Neeson PJ; Behren A; Darcy PK; Dawson SJ; Voskoboinik I; Trapani JA; Cebon J; Lehner PJ; Dawson MA
Nature; 2017 Sep; 549(7670):101-105. PubMed ID: 28813417
[TBL] [Abstract][Full Text] [Related]
18. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells.
Sato H; Niimi A; Yasuhara T; Permata TBM; Hagiwara Y; Isono M; Nuryadi E; Sekine R; Oike T; Kakoti S; Yoshimoto Y; Held KD; Suzuki Y; Kono K; Miyagawa K; Nakano T; Shibata A
Nat Commun; 2017 Nov; 8(1):1751. PubMed ID: 29170499
[TBL] [Abstract][Full Text] [Related]
19. The clinical and prognostic significance of CMTM6/PD-L1 in oncology.
Yaseen MM; Abuharfeil NM; Darmani H
Clin Transl Oncol; 2022 Aug; 24(8):1478-1491. PubMed ID: 35278198
[TBL] [Abstract][Full Text] [Related]
20. Construction of stable membranal CMTM6-PD-L1 full-length complex to evaluate the PD-1/PD-L1-CMTM6 interaction and develop anti-tumor anti-CMTM6 nanobody.
Jia XM; Long YR; Yu XL; Chen RQ; Gong LK; Geng Y
Acta Pharmacol Sin; 2023 May; 44(5):1095-1104. PubMed ID: 36418428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]